Literature DB >> 17448526

Immunolocalisation of members of the polypeptide N-acetylgalactosaminyl transferase (ppGalNAc-T) family is consistent with biologically relevant altered cell surface glycosylation in breast cancer.

Susan A Brooks1, Tracey M Carter, Eric P Bennett, Henrik Clausen, Ulla Mandel.   

Abstract

An extensive family of UDP-N-alpha-d-galactosamine: polypeptide N-acetylgalactosaminyltransferases (polypeptide N-acetylgalactosaminyltransferases, ppGalNAc-T's) catalyse the attachment of the first N-acetylgalactosamine (GalNAc) monosaccharide to the polypeptide at the initiation of O-linked glycosylation of proteins. Some members of the family are broadly expressed while others are more restricted in their distribution, their expression and activity being confined to certain cells or tissues, being associated with physiological states or differentiation. Their careful regulation, which is not well understood, may mediate the synthesis of varied glycoforms of cellular proteins with different biological activities. Disruptions in glycosylation are a common feature of cancer and may have functional significance. Immunocytochemistry with confocal scanning laser microscopy was employed to detect members of the ppGalNAc-T family, ppGalNAc-T1, -T2, -T3, -T4 and -T6 in a range of breast cell lines. The cells were chosen to represent a range of phenotypes from 'normal'/benign (HMT 3,522), primary, non-metastatic breast cancer (BT 474), to aggressive, metastatic breast cancer (ZR75-1, T47D, MCF-7, DU 4,475). They stably synthesise varying levels, consistent with origin and phenotype, of aberrantly glycosylated glycoproteins featuring exposed, terminal GalNAc residues, including the cancer-associated Tn antigen, which, in numerous studies, have been associated with metastatic competence and poor cancer prognosis. GalNAc-T1 and -T2 were detectable at low levels in all cell lines studied. ppGalNAc-T4, which has never been described in breast, was very weakly detectable in BT 474, MCF7 and T47D. ppGalNAc-T3 and -T6 were weakly detectable or undetectable, respectively, in the cell line HMT 3,522 derived from 'normal'/benign breast epithelium, but were readily detectable in all malignant cell lines. Thus, a broader range of ppGalNAc-T's were detectable in the malignant cell lines in comparison to the 'normal'/benign cells, where only the 'housekeeping' ppGalNAc-T1 and -T2 were present. Expression of normally tightly restricted ppGalNAc-T's may result in initiation of O-linked glycosylation at normally unoccupied potential glycosylation sites leading to altered glycoforms of proteins with changed biological activity which may contribute to the pathogenesis of cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17448526     DOI: 10.1016/j.acthis.2007.02.009

Source DB:  PubMed          Journal:  Acta Histochem        ISSN: 0065-1281            Impact factor:   2.479


  19 in total

1.  Development of isoform-specific sensors of polypeptide GalNAc-transferase activity.

Authors:  Lina Song; 丽娜 宋; Collin Bachert; Katrine T Schjoldager; Henrik Clausen; Adam D Linstedt
Journal:  J Biol Chem       Date:  2014-09-15       Impact factor: 5.157

2.  Expression of UDP-N-acetyl-D-galactosamine: polypeptide N-acetylgalactosaminyltransferase-6 in gastric mucosa, intestinal metaplasia, and gastric carcinoma.

Authors:  Joana Gomes; Nuno T Marcos; Nora Berois; Eduardo Osinaga; Ana Magalhães; João Pinto-de-Sousa; Raquel Almeida; Fátima Gärtner; Celso A Reis
Journal:  J Histochem Cytochem       Date:  2008-10-14       Impact factor: 2.479

3.  N-Acetylgalactosaminyltransferase-14 as a potential biomarker for breast cancer by immunohistochemistry.

Authors:  Chen Wu; Xiaodan Guo; Weina Wang; Yun Wang; Yaojun Shan; Bo Zhang; Wenqian Song; Sisi Ma; Jianfeng Ge; Hao Deng; Mingsheng Zhu
Journal:  BMC Cancer       Date:  2010-04-01       Impact factor: 4.430

4.  Engineering of N. benthamiana L. plants for production of N-acetylgalactosamine-glycosylated proteins--towards development of a plant-based platform for production of protein therapeutics with mucin type O-glycosylation.

Authors:  Sasha M Daskalova; Josiah E Radder; Zbigniew A Cichacz; Sam H Olsen; George Tsaprailis; Hugh Mason; Linda C Lopez
Journal:  BMC Biotechnol       Date:  2010-08-24       Impact factor: 2.563

Review 5.  Aberrant O-glycosylation and anti-glycan antibodies in an autoimmune disease IgA nephropathy and breast adenocarcinoma.

Authors:  Milada Stuchlová Horynová; Milan Raška; Henrik Clausen; Jan Novak
Journal:  Cell Mol Life Sci       Date:  2012-08-03       Impact factor: 9.261

6.  Loss of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 3 and reduced O-glycosylation in colon carcinoma cells selected for hepatic metastasis.

Authors:  Kentaro Kato; Hideyuki Takeuchi; Akira Kanoh; Naoki Miyahara; Yoko Nemoto-Sasaki; Megumi Morimoto-Tomita; Azusa Matsubara; Yoshimi Ohashi; Michihiko Waki; Katsuaki Usami; Ulla Mandel; Henrik Clausen; Nobuaki Higashi; Tatsuro Irimura
Journal:  Glycoconj J       Date:  2010-02       Impact factor: 2.916

7.  Probing isoform-specific functions of polypeptide GalNAc-transferases using zinc finger nuclease glycoengineered SimpleCells.

Authors:  Katrine T-B G Schjoldager; Sergey Y Vakhrushev; Yun Kong; Catharina Steentoft; Aaron S Nudelman; Nis B Pedersen; Hans H Wandall; Ulla Mandel; Eric P Bennett; Steven B Levery; Henrik Clausen
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-07       Impact factor: 11.205

Review 8.  The Cosmc connection to the Tn antigen in cancer.

Authors:  Tongzhong Ju; Rajindra P Aryal; Matthew R Kudelka; Yingchun Wang; Richard D Cummings
Journal:  Cancer Biomark       Date:  2014-01-01       Impact factor: 4.388

9.  Glycosyltransferases as Markers for Early Tumorigenesis.

Authors:  Ulrich Andergassen; Friederike Liesche; Alexandra C Kölbl; Matthias Ilmer; Stefan Hutter; Klaus Friese; Udo Jeschke
Journal:  Biomed Res Int       Date:  2015-06-16       Impact factor: 3.411

Review 10.  Altered glycosylation in cancer: A promising target for biomarkers and therapeutics.

Authors:  Divya Thomas; Ashok Kumar Rathinavel; Prakash Radhakrishnan
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-11-04       Impact factor: 10.680

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.